引用本文:张娜,赵帅,朱晓艳,等.2021-2025年山东省ART失败HIV感染者耐药特征及影响因素分析[J].预防医学论坛,2025,32(2):81-87.10.16406/j.pmt.issn.1672-9153.2026.02.01

下载全文:https://kns.cnki.net/kcms2/article/abstract?v=Y48PYOiatWcEThSyEcFOINEuWYGqg0XX68-4pjpeyWOdcu8j8JgBcTj6J5bo00CuAwhkM3dWSjPcSw5dkeYOtuDQJP0YbcQ_AX2dtrVdelzh3UBECbcPhi67GASfJ9p9UOJmy2-jxd8jNH9ouInBfVhiYMUPA5bvYD-vIXkWB5z76p2RVg4lcQ==

2021-2025年山东省ART失败HIV感染者耐药特征及影响因素分析

张娜1,2,赵帅1,2,朱晓艳1,2,袁飞怡3,孙晓光1,2,别梦雨1,王国永1,2

Zhang Na,Zhao Shuai,Zhu Xiaoyan,Yuan Feiyi,Sun Xiaoguang,Bie Mengyu,Wang Guoyong

摘要:目的 分析山东省艾滋病抗逆转录病毒治疗(antiretroviral therapy, ART)失败者耐药特征及其影响因素,为优化治疗策略提供依据。方法 收集山东省2021年1月-2025年12月治疗失败HIV感染者血浆样本,进行基因型耐药检测,采用χ~2检验和多因素logistic回归分析耐药相关因素。结果 共纳入成功扩增样本1 418例,总耐药率为50.28%。非核苷类逆转录酶抑制剂(non-nucleoside reverse transcriptase inhibitors, NNRTIs)耐药率最高(45.91%),其次为核苷类逆转录酶抑制剂(nucleotide reverse transcriptase inhibitor, NRTIs)(30.89%)。NRTIs耐药突变位点以M184V为主,突变率42.64%;NNRTIs以K103N为主,突变率41.80%;蛋白酶抑制剂(protease inhibitors, PIs)以I54L为主,突变率13.46%。多因素分析显示,文化程度为初中(OR=1.466 8,95%CI:1.033 2~2.082 3)、小学及以下(OR=2.262 0,95%CI:1.470 8~3.478 6),经同性传播(OR=1.425 2,95%CI:1.105 8~1.836 9),从事流动服务工作(OR=1.538 5,95%CI:1.161 9~2.037 2)和其他(OR=1.566 4,95%CI:1.027 4~2.388 1),治疗基线CD4<200 cells/μL(OR=3.907 1,95%CI:2.755 1~5.540 8)、200~<350 cells/μL(OR=1.772 6,95%CI:1.256 7~2.500 2),350~<500 cells/μL(OR=1.546 7,95%CI:1.074 5~2.226 4),基因亚型为CRF01_AE(OR=1.700 5,95%CI:1.272 6~2.272 1)的HIV感染者发生耐药的风险较高,治疗基线方案含PIs的发生耐药风险较低(OR=0.131 9,95%CI:0.043 5~0.400 0)。结论 山东省ART失败者耐药率较高,以NNRTIs类耐药为主;耐药位点呈多样性;耐药发生与文化程度、职业、传播途径、治疗基线免疫状态、初始治疗方案及病毒亚型有关,需优化治疗方案、强化耐药监测,关注重点人群,通过多维度干预有效遏制耐药毒株发生和传播。


Abstract:Objective To analyze the drug resistance characteristics and influencing factors among HIV-infected individuals who experienced antiretroviral therapy(ART) failure in Shandong Province,providing evidence for optimizing treatment strategies.Methods Plasma samples were collected from HIV-infected individuals with treatment failure in Shandong Province between January 2021 and December 2025.Genotypic drug resistance testing was performed,and χ~2 tests and multivariate logistic regression were used to analyze factors associated with drug resistance.Results A total of 1 418 successfully amplified samples were included,with an overall drug resistance rate of 50.28%.The resistance rate to non-nucleoside reverse transcriptase inhibitors(NNRTIs) was the highest(45.91%),followed by nucleotide reverse transcriptase inhibitors(NRTIs)(30.89%).The primary resistance mutation for NRTIs was M184V(mutation rate:42.64%),while for NNRTIs it was K103N(mutation rate:41.80%).The main protease inhibitor(PIs) mutation was I54L(mutation rate:13.46%).Multivariate analysis showed that individuals with a junior high school education(OR=1.466 8,95% CI:1.033 2-2.082 3) or primary school and below(OR=2.262 0,95% CI:1.470 8-3.478 6),those infected via homosexual transmission(OR=1.425 2,95% CI:1.105 8-1.836 9),individuals working in mobile servicejobs(OR=1.5385,95%CI:1.1619-2.037 2) or other occupations(OR=1.566 4,95% CI:1.027 4-2.388 1),and those with baseline CD4 counts <200 cells/μL(OR=3.907 1,95% CI:2.755 1-5.540 8),200-<350 cells/μL(OR=1.772 6,95% CI:1.256 7-2.500 2),or 350-<500 cells/μL(OR=1.546 7,95% CI:1.074 5-2.226 4) had a higher risk of drug resistance.Additionally,individuals with the CRF01_AE genotype(OR=1.700 5,95% CI:1.272 6-2.272 1) were at increased risk,whereas those on a baseline treatment regimen containing PIs had a lower risk of drug resistance(OR=0.131 9,95% CI:0.043 5-0.400 0).Conclusion The drug resistance rate among individuals with ART failure in Shandong Province is relatively high,predominantly involving NNRTIs.Resistance sites are diverse.Drug resistance is associated with education level,occupation,transmission route,baseline immune status,initial treatment regimen,and viral genotype.It is necessary to optimize treatment regimens,strengthen drug resistance monitoring,focus on key populations,and implement multidimensional interventions to effectively curb the emergence and transmission of drug-resistant strains.

关键词: 艾滋病;人类免疫缺陷病毒;抗逆转录病毒治疗;基因型耐药
KeyWords:AIDS;Human immunodeficiency virus;Antiretroviral therapy;Genotypic resistance

基金项目: 山东省自然科学基金(ZR2025MS1319);; 山东省医药卫生科技项目(202312050984)

DOI:10.16406/j.pmt.issn.1672-9153.2026.02.01

上一篇:《2023-2024年威海市HIV-1基因亚型及分子传播网络特征分析》

下一篇:《冲突、流动性与本迪布焦埃博拉病毒病:基于刚果(金)第17次疫情的评述——兼论跨境传播、检测困境与社区信任重建》